Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Edgewise Therapeutics < Previous 1 2 Next > Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society October 01, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) September 19, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time September 17, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 08, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 May 10, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors May 07, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) May 06, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies April 23, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) April 15, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session March 28, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 March 27, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 March 05, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference February 28, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 22, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) February 13, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock January 19, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference January 09, 2024 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 December 19, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community December 18, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA November 30, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 09, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present at Upcoming Investor Conferences November 08, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023 November 01, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne) October 26, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society September 27, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker) September 26, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction September 14, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights August 10, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) June 26, 2023 From Edgewise Therapeutics Via Business Wire Tickers EWTX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.